{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T01:42:38Z","timestamp":1790818958594,"version":"4.1.0"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,5,4]],"date-time":"2022-05-04T00:00:00Z","timestamp":1651622400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,5,4]],"date-time":"2022-05-04T00:00:00Z","timestamp":1651622400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"GlaxoSmithKline Biologicals SA"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Respir Res"],"published-print":{"date-parts":[[2022,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Non-typeable <jats:italic>Haemophilus influenzae<\/jats:italic> (NTHi) and <jats:italic>Moraxella catarrhalis<\/jats:italic> (Mcat) infections are frequently associated with exacerbations of chronic obstructive pulmonary disease (COPD). Results were reported with a two-dose (0\u20132\u00a0months) schedule of an investigational AS01<jats:sub>E<\/jats:sub>-adjuvanted NTHi-Mcat vaccine containing three surface proteins from NTHi and one from Mcat. We evaluated the safety and immunogenicity of three NTHi-Mcat vaccine doses administered in two different schedules to adults with a smoking history (\u2265\u200910 pack-years), immunologically representing the COPD population.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>In this 18-month, randomised (1:1), observer-blind study with 6-month open follow-up, 200 healthy adults aged 40\u201380\u00a0years received NTHi-Mcat vaccine at 0\u20132\u20136\u00a0months and placebo at 12\u00a0months (0\u20132\u20136 group), or vaccine at 0\u20132\u201312\u00a0months and placebo at 6\u00a0months (0\u20132\u201312 group). Solicited and unsolicited adverse events (AEs) were recorded for 7 and 30\u00a0days, respectively, post-vaccination, and potential immune-mediated diseases (pIMDs) and serious AEs (SAEs) throughout the study. Immune responses were assessed.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>No safety concerns were identified with the third vaccine dose or overall. Most solicited AEs were mild\/moderate. Unsolicited AEs were reported in 16%, 16.1% and 14.4% of participants in the 0\u20132\u20136 group post-dose 1, 2 and 3, respectively, and 20%, 20.4% and 9.7%, respectively, in the 0\u20132\u201312 group. In 24\u00a0months, SAEs were reported in 12 participants in the 0\u20132\u20136 group and 9 in the 0\u20132\u201312 group (18 events in each group). There were three deaths (unknown cause, 0\u20132\u20136 group; myocardial infarction, lung cancer in 0\u20132\u201312 group). pIMDs were reported in three participants in the 0\u20132\u20136 group (non-serious inflammatory bowel disease, gout, psoriasis) and three in the 0\u20132\u201312 group (serious ulcerative colitis, two with non-serious gout). The SAEs, deaths and pIMDs were considered not causally related to vaccination. Antigen-specific antibody concentrations were higher at 12\u00a0months post-dose 1 with the 0\u20132\u20136 schedule than with the 0\u20132\u201312 schedule and at 12\u00a0months post-dose 3 were similar between schedules, remaining higher than baseline.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>No safety concerns were identified when the investigational NTHi-Mcat vaccine was administered via a 0\u20132\u20136\u00a0months or 0\u20132\u201312\u00a0months schedule to older adults with a smoking history. Persistent immune responses were observed after the third vaccine dose.<\/jats:p>\n                <jats:p><jats:italic>Trial registration<\/jats:italic><jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/clinicaltrials.gov\/\">https:\/\/clinicaltrials.gov\/<\/jats:ext-link>; NCT03443427, registered February 23, 2018.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12931-022-02019-4","type":"journal-article","created":{"date-parts":[[2022,5,4]],"date-time":"2022-05-04T12:03:05Z","timestamp":1651665785000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Safety and immunogenicity of three doses of non-typeable Haemophilus influenzae-Moraxella catarrhalis (NTHi-Mcat) vaccine when administered according to two different schedules: a phase 2, randomised, observer-blind study"],"prefix":"10.1186","volume":"23","author":[{"given":"Ilaria","family":"Galgani","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margherita","family":"Annaratone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniela","family":"Casula","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gennaro","family":"Di Maro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michel","family":"Janssens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annaelisa","family":"Tasciotti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tino","family":"Schwarz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Murdo","family":"Ferguson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashwani Kumar","family":"Arora","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,5,4]]},"reference":[{"key":"2019_CR1","doi-asserted-by":"publisher","first-page":"1736","DOI":"10.1016\/S0140-6736(18)32203-7","volume":"392","author":"GBD 2017 Causes of Death Collaborators","year":"2018","unstructured":"GBD 2017 Causes of Death Collaborators. Global, regional, and national age-sex-specific mortality for 282 causes of death in 195 countries and territories, 1980\u20132017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet. 2018;392:1736\u201388.","journal-title":"Lancet"},{"key":"2019_CR2","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1111\/resp.14007","volume":"26","author":"P Lange","year":"2021","unstructured":"Lange P, Ahmed E, Lahmar ZM, Martinez FJ, Bourdin A. Natural history and mechanisms of COPD. Respirology. 2021;26:298\u2013321.","journal-title":"Respirology"},{"key":"2019_CR3","unstructured":"Global Initiative for Chronic Obstructive Lung Disease. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. 2022 report. https:\/\/goldcopd.org\/wp-content\/uploads\/2021\/12\/GOLD-REPORT-2022-v1.1-22Nov2021_WMV.pdf. Accessed 14 Apr 2022."},{"key":"2019_CR4","doi-asserted-by":"publisher","first-page":"105988","DOI":"10.1016\/j.rmed.2020.105988","volume":"173","author":"CM Njoku","year":"2020","unstructured":"Njoku CM, Alqahtani JS, Wimmer BC, Peterson GM, Kinsman L, Hurst JR, et al. Risk factors and associated outcomes of hospital readmission in COPD: A systematic review. Respir Med. 2020;173:105988.","journal-title":"Respir Med"},{"key":"2019_CR5","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1097\/MCP.0000000000000268","volume":"22","author":"R Dy","year":"2016","unstructured":"Dy R, Sethi S. The lung microbiome and exacerbations of COPD. Curr Opin Pulm Med. 2016;22:196\u2013202.","journal-title":"Curr Opin Pulm Med"},{"key":"2019_CR6","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/j.trsl.2016.06.007","volume":"179","author":"YJ Huang","year":"2017","unstructured":"Huang YJ, Erb-Downward JR, Dickson RP, Curtis JL, Huffnagle GB, Han MK. Understanding the role of the microbiome in chronic obstructive pulmonary disease: principles, challenges, and future directions. Transl Res. 2017;179:71\u201383.","journal-title":"Transl Res"},{"key":"2019_CR7","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1136\/thoraxjnl-2017-210408","volume":"73","author":"D Mayhew","year":"2018","unstructured":"Mayhew D, Devos N, Lambert C, Brown JR, Clarke SC, Kim VL, et al. Longitudinal profiling of the lung microbiome in the AERIS study demonstrates repeatability of bacterial and eosinophilic COPD exacerbations. Thorax. 2018;73:422\u201330.","journal-title":"Thorax"},{"key":"2019_CR8","doi-asserted-by":"publisher","first-page":"919","DOI":"10.1136\/thoraxjnl-2016-209023","volume":"72","author":"TMA Wilkinson","year":"2017","unstructured":"Wilkinson TMA, Aris E, Bourne S, Clarke SC, Peeters M, Pascal TG, et al. A prospective, observational cohort study of the seasonal dynamics of airway pathogens in the aetiology of exacerbations in COPD. Thorax. 2017;72:919\u201327.","journal-title":"Thorax"},{"key":"2019_CR9","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1056\/NEJMoa012561","volume":"347","author":"S Sethi","year":"2002","unstructured":"Sethi S, Evans N, Grant BJ, Murphy TF. New strains of bacteria and exacerbations of chronic obstructive pulmonary disease. N Engl J Med. 2002;347:465\u201371.","journal-title":"N Engl J Med"},{"key":"2019_CR10","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1186\/s12931-021-01653-8","volume":"22","author":"L Malvisi","year":"2021","unstructured":"Malvisi L, Taddei L, Yarraguntla A, Wilkinson TMA, Arora AK. Sputum sample positivity for Haemophilus influenzae or Moraxella catarrhalis in acute exacerbations of chronic obstructive pulmonary disease: evaluation of association with positivity at earlier stable disease timepoints. Respir Res. 2021;22:67.","journal-title":"Respir Res"},{"issue":"1","key":"2019_CR11","doi-asserted-by":"publisher","first-page":"00614","DOI":"10.1183\/23120541.00614-2020","volume":"7","author":"F Saliu","year":"2021","unstructured":"Saliu F, Rizzo G, Bragonzi A, Cariani L, Cirillo DM, Colombo C, et al. Chronic infection by nontypeable Haemophilus influenzae fuels airway inflammation. ERJ Open Res. 2021;7(1):00614\u20132020.","journal-title":"ERJ Open Res."},{"key":"2019_CR12","doi-asserted-by":"publisher","first-page":"1661","DOI":"10.1086\/517611","volume":"195","author":"TT Tan","year":"2007","unstructured":"Tan TT, Morgelin M, Forsgren A, Riesbeck K. Haemophilus influenzae survival during complement-mediated attacks is promoted by Moraxella catarrhalis outer membrane vesicles. J Infect Dis. 2007;195:1661\u201370.","journal-title":"J Infect Dis"},{"key":"2019_CR13","doi-asserted-by":"publisher","first-page":"e00102","DOI":"10.1128\/mBio.00102-10","volume":"1","author":"CE Armbruster","year":"2010","unstructured":"Armbruster CE, Hong W, Pang B, Weimer KE, Juneau RA, Turner J, et al. Indirect pathogenicity of Haemophilus influenzae and Moraxella catarrhalis in polymicrobial otitis media occurs via interspecies quorum signaling. MBio. 2010;1:e00102\u201310.","journal-title":"MBio."},{"key":"2019_CR14","doi-asserted-by":"publisher","first-page":"3845","DOI":"10.1128\/AAC.01772-10","volume":"55","author":"V Schaar","year":"2011","unstructured":"Schaar V, Nordstr\u00f6m T, M\u00f6rgelin M, Riesbeck K. Moraxella catarrhalis outer membrane vesicles carry beta-lactamase and promote survival of Streptococcus pneumoniae and Haemophilus influenzae by inactivating amoxicillin. Antimicrob Agents Chemother. 2011;55:3845\u201353.","journal-title":"Antimicrob Agents Chemother"},{"key":"2019_CR15","doi-asserted-by":"publisher","first-page":"3113","DOI":"10.1016\/j.vaccine.2019.04.041","volume":"37","author":"P Van Damme","year":"2019","unstructured":"Van Damme P, Leroux-Roels G, Vandermeulen C, De Ryck I, Tasciotti A, Dozot M, et al. Safety and immunogenicity of non-typeable Haemophilus influenzae-Moraxella catarrhalis vaccine. Vaccine. 2019;37:3113\u201322.","journal-title":"Vaccine"},{"key":"2019_CR16","doi-asserted-by":"publisher","first-page":"3156","DOI":"10.1016\/j.vaccine.2016.04.051","volume":"34","author":"G Leroux-Roels","year":"2016","unstructured":"Leroux-Roels G, Van Damme P, Haazen W, Shakib S, Caubet M, Aris E, et al. Phase I, randomized, observer-blind, placebo-controlled studies to evaluate the safety, reactogenicity and immunogenicity of an investigational non-typeable Haemophilus influenzae (NTHi) protein vaccine in adults. Vaccine. 2016;34:3156\u201363.","journal-title":"Vaccine"},{"key":"2019_CR17","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1183\/09031936.00010407","volume":"31","author":"B Barcel\u00f3","year":"2008","unstructured":"Barcel\u00f3 B, Pons J, Ferrer JM, Sauleda J, Fuster A, Agust\u00ed AG. Phenotypic characterisation of T-lymphocytes in COPD: abnormal CD4+CD25+ regulatory T-lymphocyte response to tobacco smoking. Eur Respir J. 2008;31:555\u201362.","journal-title":"Eur Respir J"},{"key":"2019_CR18","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1186\/1465-9921-6-68","volume":"6","author":"D Droemann","year":"2005","unstructured":"Droemann D, Goldmann T, Tiedje T, Zabel P, Dalhoff K, Schaaf B. Toll-like receptor 2 expression is decreased on alveolar macrophages in cigarette smokers and COPD patients. Respir Res. 2005;6:68.","journal-title":"Respir Res"},{"key":"2019_CR19","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1183\/09031936.99.14230999","volume":"14","author":"S Takanashi","year":"1999","unstructured":"Takanashi S, Hasegawa Y, Kanehira Y, Yamamoto K, Fujimoto K, Satoh K, et al. Interleukin-10 level in sputum is reduced in bronchial asthma, COPD and in smokers. Eur Respir J. 1999;14:309\u201314.","journal-title":"Eur Respir J"},{"key":"2019_CR20","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1080\/14760584.2016.1213632","volume":"16","author":"AM Didierlaurent","year":"2017","unstructured":"Didierlaurent AM, Laup\u00e8ze B, Di Pasquale A, Hergli N, Collignon C, Gar\u00e7on N. Adjuvant system AS01: helping to overcome the challenges of modern vaccines. Expert Rev Vaccines. 2017;16:55\u201363.","journal-title":"Expert Rev Vaccines"},{"key":"2019_CR21","unstructured":"Andreas S, Testa M, Boyer L, Brusselle G, Janssens W, Kerwin E, et al. Non-typeable Haemophilus influenzae-Moraxella catarrhalis vaccine for the prevention of exacerbations in chronic obstructive pulmonary disease: a multicentre, randomised, placebo-controlled, observer-blinded, proof-of-concept, phase 2b trial. Lancet Respir Med 2022; S2213-2600(21)00502-6."},{"key":"2019_CR22","doi-asserted-by":"publisher","first-page":"1870","DOI":"10.1016\/j.vaccine.2013.01.042","volume":"31","author":"F TavaresDaSilva","year":"2013","unstructured":"Tavares Da Silva F, De Keyser F, Lambert PH, Robinson WH, Westhovens R, Sindic C. Optimal approaches to data collection and analysis of potential immune mediated disorders in clinical trials of new vaccines. Vaccine. 2013;31:1870\u20136.","journal-title":"Vaccine"},{"key":"2019_CR23","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1007\/s10875-010-9490-6","volume":"31","author":"P Moris","year":"2011","unstructured":"Moris P, van der Most R, Leroux-Roels I, Clement F, Dram\u00e9 M, Hanon E, et al. H5N1 influenza vaccine formulated with AS03A induces strong cross-reactive and polyfunctional CD4 T-cell responses. J Clin Immunol. 2011;31:443\u201354.","journal-title":"J Clin Immunol"},{"key":"2019_CR24","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1093\/biomet\/26.4.404","volume":"26","author":"CJ Clopper","year":"1934","unstructured":"Clopper CJ, Pearson ES. The use of confidence or fiducial limits illustrated in the case of the binomial. Biometrika. 1934;26:404\u201313.","journal-title":"Biometrika"},{"key":"2019_CR25","doi-asserted-by":"publisher","first-page":"6102","DOI":"10.1016\/j.vaccine.2019.07.100","volume":"37","author":"TMA Wilkinson","year":"2019","unstructured":"Wilkinson TMA, Schembri S, Brightling C, Bakerly ND, Lewis K, MacNee W, et al. Non-typeable Haemophilus influenzae protein vaccine in adults with COPD: A phase 2 clinical trial. Vaccine. 2019;37:6102\u201311.","journal-title":"Vaccine"},{"key":"2019_CR26","doi-asserted-by":"publisher","first-page":"1920","DOI":"10.4049\/jimmunol.1400948","volume":"193","author":"AM Didierlaurent","year":"2014","unstructured":"Didierlaurent AM, Collignon C, Bourguignon P, Wouters S, Fierens K, Fochesato M, et al. Enhancement of adaptive immunity by the human vaccine adjuvant AS01 depends on activated dendritic cells. J Immunol. 2014;193:1920\u201330.","journal-title":"J Immunol"}],"container-title":["Respiratory Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12931-022-02019-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12931-022-02019-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12931-022-02019-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,4]],"date-time":"2022-05-04T12:06:36Z","timestamp":1651665996000},"score":1,"resource":{"primary":{"URL":"https:\/\/respiratory-research.biomedcentral.com\/articles\/10.1186\/s12931-022-02019-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5,4]]},"references-count":26,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["2019"],"URL":"https:\/\/doi.org\/10.1186\/s12931-022-02019-4","relation":{},"ISSN":["1465-993X"],"issn-type":[{"value":"1465-993X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,5,4]]},"assertion":[{"value":"12 October 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 April 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 May 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was conducted in accordance with the Declaration of Helsinki and Good Clinical Practice. The protocols and associated documents were reviewed and approved by the ethics committee of each participating centre (in Canada, IRB services [SSU00044837, SSU00044747]; in Germany, Ethikkommission der \u00c4rztekammer Nordrhein and Ethik-Kommission der Medizinischen Fakult\u00e4t der Julius-Maximilians-Universit\u00e4t W\u00fcrzburg Institut f\u00fcr Pharmakologie und Toxikologie; in UK, East of England\u2014Cambridgeshire and Hertfordshire Research Ethics Committee [17\/EE\/0450]). All participants provided written informed consent before study entry.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"IG, MA, DC, GDM, MJ, AT, and AKA are employed by the GSK group of companies. IG holds shares in the GSK group of companies. DC declares two pending patents (unpublished) and AKA declares a published patent application \u2018Methods of Boosting the Immune Response\u2019. TS has received honoraria for lecturing from the GSK group of companies, Pfizer, Bavarian Nordic, Janssen-Cilag, AstraZeneca and Sanofi and personal fees during the conduct of this study from the GSK group of companies, Pfizer, Biogen, Merck Serono, Biotest, Sequirus, Bavarian Nordic, and Sanofi. MF is employed by the Colchester Research Group which received payment from the GSK group of companies for the conduct of this study. The wife of MF is the owner of the Colchester Research Group. IG, MA, DC, GDM, MJ, AT, AKA, TS and MF declare no other financial and non-financial relationships and activities.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"114"}}